CiRC Biosciences

Executive Summary

CiRC Biosciences is a private regenerative medicine company based in Cambridge, MA, leveraging its proprietary cellular reprogramming platform to generate new, functional cells for the treatment of degenerative diseases. Founded in 2021, the company initially targets serious ophthalmic conditions with high unmet need, such as retinal degenerative diseases leading to vision loss. By reprogramming a patient's own cells to replace damaged tissue, CiRC aims to restore function and reverse disease progression, an approach that differs from traditional small molecule or gene therapies that only slow decline. The platform has broad potential across other tissue types, but ophthalmology represents a tractable entry point with clear clinical endpoints.

Upcoming Catalysts (preview)

• Q2 2027IND filing for lead ophthalmic program70% success
• Q2 2026Presentation of preclinical proof-of-concept data at ARVO 202690% success
• Q4 2026Series A financing announcement to support clinical development75% success